These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27899263)

  • 21. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.
    Seo H; Ye BD; Song EM; Lee SH; Chang K; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK
    Dig Dis Sci; 2017 Oct; 62(10):2882-2893. PubMed ID: 28822006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients.
    Peters CP; Eshuis EJ; Toxopeüs FM; Hellemons ME; Jansen JM; D'Haens GR; Fockens P; Stokkers PC; Tuynman HA; van Bodegraven AA; Ponsioen CY;
    J Crohns Colitis; 2014 Aug; 8(8):866-75. PubMed ID: 24491515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
    Bouguen G; Laharie D; Nancey S; Hebuterne X; Flourie B; Filippi J; Roblin X; Trang C; Bourreille A; Babouri A; Bretagne JF; Siproudhis L; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2015 May; 21(5):1047-53. PubMed ID: 25803504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adalimumab as induction therapy for Crohn's disease - one center study].
    Gonciarz M; Mularczyk A; Szkudłapski D; Piątek I; Kopała M
    Pol Merkur Lekarski; 2016 Nov; 41(245):216-220. PubMed ID: 27883347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
    Faubion WA; Dubinsky M; Ruemmele FM; Escher J; Rosh J; Hyams JS; Eichner S; Li Y; Reilly N; Thakkar RB; Robinson AM; Lazar A
    Inflamm Bowel Dis; 2017 Mar; 23(3):453-460. PubMed ID: 28129288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
    Einarson TR; Bereza BG; Ying Lee X; Lelli F
    Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of adalimumab for Crohn's disease in real clinical practice].
    Knyazev OV; Kagramanova AV; Ruchkina IN; Fadeeva NA; Lishchinskaya AA; Boldyreva ON; Zhulina EY; Shcherbakov PL; Orlova NV; Kirova MV; Parfenov AI
    Ter Arkh; 2017; 89(2):20-27. PubMed ID: 28281511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
    Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
    J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Adalimumab in Korean Patients with Crohn's Disease.
    Sohn IW; Kim ST; Kim B; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
    Gut Liver; 2016 Mar; 10(2):255-61. PubMed ID: 26470766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis.
    Olivares D; Alba C; Pérez I; Roales V; Rey E; Taxonera C
    Rev Esp Enferm Dig; 2019 Nov; 111(11):846-851. PubMed ID: 31566410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease.
    Kariyawasam VC; Ward MG; Blaker PA; Patel KV; Goel R; Sanderson JD; Irving PM
    Inflamm Bowel Dis; 2017 Sep; 23(9):1555-1565. PubMed ID: 28786865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
    Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
    Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
    Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL
    BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.
    Orlando A; Renna S; Mocciaro F; Cappello M; Di Mitri R; Randazzo C; Cottone M
    Inflamm Bowel Dis; 2012 May; 18(5):826-31. PubMed ID: 21837774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.